Nature Biotechnology, Published online: 30 June 2026; doi:10.1038/s41587-026-03200-6
Each year, Nature Biotechnology highlights companies that received sizeable early-stage funding in the previous year. Trogenix has developed a platform for generating ‘synthetic super-enhancers’ that could drive highly cell-specific gene therapy-based treatment of solid tumors such as glioblastoma.